⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKTX News
Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
globenewswire.com
AKTX
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
globenewswire.com
AKTX
ReAlta Life Sciences Announces Appointment of Kia Motesharei, Ph.D. to Board of Directors
businesswire.com
MDGL
AKTX
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
globenewswire.com
AKTX
Akari Therapeutics to Present at the 2026 Biotech Showcase
globenewswire.com
AKTX
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
globenewswire.com
AKTX
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
globenewswire.com
AKTX
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
globenewswire.com
AKTX
Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
globenewswire.com
AKTX
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
globenewswire.com
AKTX